Pulmonary Arterial Hypertension
For most patients in early stages of pulmonary arterial hypertension, the use of bosentan (Tracleer) seems able to inhibit the development of worsening symptoms of pulmonary arterial hypertension, the researchers said.
"Our experimental results confirm the first diagnosis and early treatment of pulmonary arterial hypertension have an impact on the outcome such as clinical deterioration, even for patients with pulmonary arterial hypertension who currently suffering from symptoms of being," said Nazzareno Galie Kardialog, MD, of University of Bologna in Italy.
Approximately 100.0000 patients in the United States who suffer from pulmonary arterial hypertension that increased right heart pressure, causing enlargement and eventually heart failure.
Dr. Galie and colleagues recruited 185 patients with pulmonary arterial hypertension, aged 12 years and more, into the endothelin antagonist Trial in Mildly symptomatic patients. They set in 1993 granted with bosentan 62.5 mg twice daily for four weeks and then 125 mg twice daily after one month during the study. 92 patients pulmonary arterial hypertension were given placebo.
For determine a decrease of conditions, patients pulmonary arterial hypertension are given values according to the level of lung vascular resistance at the beginning of the experiment and at the end of the study. Among patients with pulmonary arterial hypertension using bosentan, resistance decreased to 33.5%, while resistance decreased 10% occur among patients pulmonary arterial hypertension who received placebo.
He said with bosentan dose of 2 mg / kg and 4 mg / kg for children aged two to 11 can survive well in 36 children with pulmonary arterial hypertension in the study.
"This study is a continuation of the important developments in the field," commented Daniel Jones, MD, dean of the faculty of medicine University of Mississippi in Jackson, and president of the American Heart Association. New drugs such as bosentan has improved dramatically in patients with pulmonary arterial hypertension.
He said with bosentan dose of 2 mg / kg and 4 mg / kg for children aged two to 11 can survive well in 36 children with pulmonary arterial hypertension in the study.
"This study is a continuation of the important developments in the field," commented Daniel Jones, MD, dean of the faculty of medicine University of Mississippi in Jackson, and president of the American Heart Association. New drugs such as bosentan has improved dramatically in patients with pulmonary arterial hypertension.
1. www.topnews.in
2. www.jdokter.com
